Cytokinetics (CYTK) Announces Publication of hase I and Phase IIa Clinical Trial Results for Omecamtiv Mecarbil in the Journal Lancet
Tweet Send to a Friend
Cytokinetics, Incorporated (NASDAQ: CYTK) announced today the publication of results from two clinical trials of omecamtiv mecarbil in the August ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
